

1600
Certification under 37 CFR 1.8(a)

C10 Rec'd PCT/PTO 1 9 OCT 2001

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with The United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Assistant Commissioner of Patents, Washington, D.C. 20231 on October 15, 2001.



Richard J. Streit (Reg. No. 25765)
Name

Signature

RECEIVED
FEB 12 2002
TECH CENTER 1600/2900

DOCKET: CU-2563

1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: John P. MCKEARN et al

Serial No.: 09/868,261

Group Art Unit:

Filed: June 14, 2001

Examiner:

For: Method of Using a Cyclooxygenase-2 Inhibitor and an Integrin Antagonist as a Combination Therapy in the Treatment of Neoplasia

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS
OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of the first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Date: October 15, 2001

Signature of Attorney

Richard J. Streit

Ladas & Parry


224 South Michigan Avenue

Chicago Illinois 60604

Tel. No. (312) 427-1300

Reg. No. 25765

Certification under 37 CFR 1.8(a)



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with The United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Assistant Commissioner of Patents, Washington, D.C. 20231 on October 15, 2001

Richard J. Streit (Reg. No. 25765)
Name


Signature

RECEIVED
FEB 12 2002
TECH CENTER 1600/2900

DOCKET: CU-2563

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: John P. MCKEAN et al

Serial No.: 09/868,261

Group Art Unit:

Filed: June 14, 2001

Examiner:

For: Method of Using a Cyclooxygenase-2 Inhibitor and an Integrin Antagonist as a Combination Therapy in the Treatment of Neoplasia

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit herewith patents, publications or other information of which the applicants are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose under 37 CFR 1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

The references submitted herein are listed on PTO-1449 form (modified) enclosed herewith. A copy of each reference listed is being furnished except any duplicate or cumulative patents or publications specified otherwise.

A translation of any foreign language reference, if any, is indicated in PTO-1449 form and being submitted herein if it is readily available. Otherwise it should be construed that such translation is not readily available.

Additional comments, if any, on the relevance of each reference listed are provided as follows:


Also enclosed is a copy of an International Search Report listing the cited references.

The Statement is made on the basis of the information:

<u> </u>	supplied by the inventor(s);
<u> X </u>	supplied by an individual associated with the filing and prosecution
<u> </u>	of this application (37 CFR 1.56(c)); or
<u> </u>	in the attorney's file.

Date: October 15, 2001

Respectfully submitted,



Signature of Attorney

Richard J. Streit

Ladas & Parry

224 South Michigan Avenue

Chicago Illinois 60604

Tel. No. (312) 427-1300

Reg. No. 25765